Key statistics dashboard for TuHURA Biosciences, Inc. (HURA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Stock Data
| Price | $2.03 |
| Market Cap | $129M |
| Enterprise Value | $128.7M |
| Beta | -0.32 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -3.76 |
| Price / Book | 7.02 |
| P/S | 0.00 |
| EV/EBITDA | -4.38 |
| EV/Sales | 0.00 |
| EV/FCF | -4.30 |
| P/FCF | -4.32 |
| Earnings Yield | -23.59% |
| FCF Yield | -23.13% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -154.32% |
| Return on Assets | -96.49% |
| Return on Invested Capital | -137.40% |
| Return on Capital Employed | -138.70% |
Financial Health
| Current Ratio | 0.18 |
| Quick Ratio | 0.18 |
| Cash Ratio | 0.11 |
| Debt / Equity | 0.02 |
| Debt / Assets | 1.28% |
| Net Debt / EBITDA | 0.02 |
| Interest Coverage | -27.83 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.29 |
| Cash per share | 0.02 |
| FCF per share | -0.47 |
| Tangible Book Value per share | 0.12 |
| Dividend per share | 0.00 |
Related companies: ABOS · AGEN · CGTX · INO · IRD · MCRB · SEER
Explore sector: Healthcare · Biotechnology
More sections of HURA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks